You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023212022
Dec 20233606
Jan 202410708
Feb 20244606
Mar 202460010
Apr 20243202
May 202450012
Jun 20247702
Jul 20245605
Aug 20243402
Sep 202479013
Oct 202441010
Nov 20246207
Dec 202444015
Jan 202565013
Feb 2025606
Mar 2025004
Apr 2025007
May 2025005
Jun 2025103
Total10080158